Trial reportPloS one2012
Immunohistochemical profile for unknown primary adenocarcinoma.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.The American journal of surgical pathology · 2013Trial
- Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.Biomarker research · 2026Review
- Breast cancer with scalp metastases: a case report.Journal of medical case reports · 2023Article
- Undifferentiated prostate cancer treated with docetaxel.IJU case reports · 2020Article
- Data independent acquisition-mass spectrometry (DIA-MS)-based comprehensive profiling of bone metastatic cancers revealed molecular fingerprints to assist clinical classifications for bone metastasis of unknown primary (BMUP).Translational cancer research · 2020Article
- A Machine Learning Approach for Tracing Tumor Original Sites With Gene Expression Profiles.Frontiers in bioengineering and biotechnology · 2020Article
- Effect of second primary cancer on the prognosis of patients with non-small cell lung cancer.Journal of thoracic disease · 2019Article
- An integrated tool for determining the primary origin site of metastatic tumours.Journal of clinical pathology · 2018Article
- Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.BMC cancer · 2018Article
- Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.Nature reviews. Clinical oncology · 2017Review
- KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2014Article
- Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer.Journal of thoracic disease · 2013Article
- Occult Breast Carcinoma Presenting as Scalp Metastasis.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDevelopment of tailored treatment based on immunohistochemical profiles (IPs) of tumors for cancers of unknown primary is needed. METHODOLOGY/PRINCIPAL
findingsWe developed an algorithm based on primary known adenocarcinoma for testing sensitivity and specificity. Formalin-fixed paraffin-embedded tissue samples from 71 patients of unfavorable subsets of unknown primary adenocarcinoma were obtained. We examined 15 molecular markers using the algorithm incorporating these IPs and classified the tumours into 9 subsets based on the primary tumour site. The sensitivity and specificity of this algorithm were 80.3% and 97.6%, respectively. Apparent primary sites were lung in 17 patients, digestive organs in 13, gynecological organs in 9, prostate in 7, liver or kidney in 6, breast in 4, urothelial organ in 2, biliary tract and pancreatic profile in none, and unclassified in 13. The response rate to chemotherapy was highest for the gynecological IPs. Patients with gynecological or lung cancer IPs had longer median progression-free survival than those with others: 11.2 months for gynecological IPs (p<0.001) and 6.8 months for lung IPs (p = 0.05). Lung, digestive, prostate, and gynecological profiles were associated with significantly longer median survival time than the other profiles. Multivariate analysis confirmed that the IPs were independent prognostic factors for survival. CONCLUSIONS/SIGNIFICANCE: The IPs identified in this study can be used to further stratify patient prognosis for unfavorable subsets of unknown primary adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.